The denial of the stay removes near-term uncertainty around AbbVie's 340B program revenue. Monitor the Eighth Circuit appeal for a final ruling, but the district court's strong reasoning and the state's delay in seeking the stay suggest a low probability of reversal. This is a modest positive for ABBV's 340B-related earnings stream.
ABBV drugs
ABBV drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 28 $263.20entry
- T+1 · 4mo ago +0.04%α +1.58% · $263.30
- T+5 · 4mo ago −7.37%α −11.48% · $243.80
- T+20 · 3mo ago +0.98%α −2.40% · $265.79
- T+60 · 27d ago +8.21%α +3.86% · $284.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The District of North Dakota denied North Dakota's motion to stay a permanent injunction pending appeal, keeping AbbVie's win intact. The injunction blocks enforcement of a state law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program, with AbbVie estimating the law cost it $10M in 2025 and would cost another $35M in 2026 in discounted sales. The denial removes near-term uncertainty and preserves AbbVie's ability to operate under the federal program without state-imposed penalties, a material positive for its 340B revenue stream.
Court Ruling Details
Key Facts
- Court denied North Dakota's motion to stay a permanent injunction pending appeal.
- The permanent injunction blocks enforcement of a North Dakota law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program.
- AbbVie estimated the law cost it $10 million in 2025 and will cost another $35 million in 2026 in discounted sales it would not make but for the law.
- The court found North Dakota unlikely to succeed on the merits, citing the law's criminal penalties and direct price regulation as key differences from other state laws.
- The ruling preserves the status quo and prevents North Dakota from re-imposing the law while the appeal proceeds.
Financial Impact
AbbVie estimated the law cost $10M in 2025 and will cost another $35M in 2026 in discounted sales it would not make but for the law. The denial of the stay preserves the injunction, avoiding these costs.
Risk Factors
- The Eighth Circuit could still reverse the permanent injunction on appeal, potentially re-exposing AbbVie to the law's costs.
- Other states may enact similar laws, creating ongoing legal and regulatory risk for the 340B program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2e6ca3056b-ABBV |
Track record
22 reports on ABBV
6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
- Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
- Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
- Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers